GlaxoSmithKline's HIV drug 89% more effective says study
Pharmaceuticals firm GlaxoSmithKline (GSK) said on Monday that trials of its long-acting injectable HIV drug cabotegravir administered every two months is more effective than taking daily pills in preventing HIV in women. The shares...
09 November 2020
